GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Total Assets

LLY (Eli Lilly and Co) Total Assets : $89,389 Mil (As of Mar. 2025)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Total Assets?

Eli Lilly and Co's Total Assets for the quarter that ended in Mar. 2025 was $89,389 Mil.

During the past 12 months, Eli Lilly and Co's average Total Assets Growth Rate was 40.40% per year. During the past 3 years, the average Total Assets Growth Rate was 18.80% per year. During the past 5 years, the average Total Assets Growth Rate was 14.30% per year. During the past 10 years, the average Total Assets Growth Rate was 8.20% per year.

During the past 13 years, Eli Lilly and Co's highest 3-Year average Total Assets Growth Rate was 21.30%. The lowest was -12.70%. And the median was 7.70%.

Total Assets is connected with ROA %. Eli Lilly and Co's annualized ROA % for the quarter that ended in Mar. 2025 was 13.13%. Total Assets is also linked to Revenue through Asset Turnover. Eli Lilly and Co's Asset Turnover for the quarter that ended in Mar. 2025 was 0.15.


Eli Lilly and Co Total Assets Historical Data

The historical data trend for Eli Lilly and Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Total Assets Chart

Eli Lilly and Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46,633.10 48,806.00 49,489.80 64,006.30 78,714.90

Eli Lilly and Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63,943.50 71,874.80 75,606.90 78,714.90 89,388.80

Eli Lilly and Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Eli Lilly and Co's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=14271.6+64443.3
=78,715

Eli Lilly and Co's Total Assets for the quarter that ended in Mar. 2025 is calculated as

Total Assets=Total Equity (Q: Mar. 2025 )+Total Liabilities (Q: Mar. 2025 )
=15846.8+73542
=89,389

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eli Lilly and Co  (NYSE:LLY) Total Assets Explanation

Total Assets is connected with ROA %.

Eli Lilly and Co's annualized ROA % for the quarter that ended in Mar. 2025 is

ROA %=Net Income (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=11037.2/( (78714.9+89388.8)/ 2 )
=11037.2/84051.85
=13.13 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Eli Lilly and Co's Asset Turnover for the quarter that ended in Mar. 2025 is

Asset Turnover
=Revenue (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=12728.5/( (78714.9+89388.8)/ 2 )
=12728.5/84051.85
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Eli Lilly and Co Total Assets Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Executives
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Ilya Yuffa officer: SVP and Pres, Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Daniel Skovronsky officer: SVP, CSO, and Pres. LRL LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Johna Norton officer: Senior VP, Global Quality LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285